Once-a-day stimulant is safe for ADHD, can be used after 1 year

Published Date: 13 Mar 2023

New research shows that once-daily speech-stimulating medications for the treatment of ADHD in people age 6 and older are safe and effective after one year of pain treatment.

Read Full News

Latest News

Does Caring for Grandchildren Slow Cognitive Decline?

Grandmothers who care for grandchildren show slower cognitive decline over time than non-caregivers do.

Teen Cannabis Use Tied to Increase in Serious Mental Illness

A new study shows that teens with past-year cannabis use are twice as likely to be diagnosed with psychotic or bipolar disorders within 2 years of first use.

Fertility Treatments Linked to Higher Med Use in Offspring

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

Todays Updates

Treating Depression: Crucial for Recovery From Fibromyalgia

In patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.

The Boom in ADHD Coaching Has Few Rules

Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.

SBRT May Beat Brachytherapy in Prostate Cancer

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

Todays Updates

Treating Depression: Crucial for Recovery From Fibromyalgia

In patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.

The Boom in ADHD Coaching Has Few Rules

Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.

SBRT May Beat Brachytherapy in Prostate Cancer

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

Latest News

Grandmothers who care for grandchildren show slower cognitive decline over time than non-caregivers do.

A new study shows that teens with past-year cannabis use are twice as likely to be diagnosed with psychotic or bipolar disorders within 2 years of first use.

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

News All Time

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Ultragenyx Puts BLA for MPS IIIA Gene Therapy UX111 in Front of FDA Again Noah Stansfield

Ultragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.

This Week on NeurologyLive® — February 9, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

AGNOS Study Results Demonstrate Ofatumumab’s Impact on Neurofilament Light, GFAP Marco Meglio

AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.

Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL Noah Stansfield

The FDA issued a CRL for gene therapy RGX-121 in Hunter syndrome, citing trial design and biomarker doubts; Regenxbio seeks a meeting with the agency and resubmission.

International Epilepsy Day 2026: Highlighting Gaps in Pediatric Care, Stigma, and Education Charuta Joshi, MD, Isabella Ciccone, MPH

Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents amid International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.

NeurologyLive® Friday 5 — February 6, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.

Comparative Study Reveals Psychiatric Comorbidities Common in MOGAD, MS, and NMOSD, With Distinct Timing Patterns Isabella Ciccone, MPH

A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.

Cladribine Tablets Reduce Treatment Switches, Outpatient Visits, and Health Care Costs in Multiple Sclerosis Isabella Ciccone, MPH

A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.

Innovative Trial Employs Novel PET Imaging to Track Cladribine’s Effect on Microglial Activation Louie Pasculli

The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Recommended News For You

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

Patients face high out-of-pocket costs after incident cancer diagnosis

Cancer death rates higher for children in neighborhoods with persistent poverty, study finds

EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer

Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A

Reducing social media to an hour a day boosts young people's self-image.

Schizophrenia patients are motivated by music therapy.

Recommended Articles For You

Exploring New Solutions for MCV Low: Unlocking the Potential for Improved Health 

Targeted Therapies for Breast Cancer: What’s New? 

Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment 

The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

2.

In inflammatory breast cancer, ER beta regulates estrogen signaling.

3.

Preferred and Actual Location of Death Often Don't Match for Young Cancer Patients

4.

Traces of bacteria inside brain tumors may affect tumor behavior

5.

Smart exercise planning could boost recovery for people with cancer

1.

Breaking Down the Benefits and Risks of Hematopoietic Stem Cell Transplantation 

2.

Bridging Heart and Cancer Care: The Essential Framework of a Modern Cardio-Oncology Program

3.

Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances

4.

Everything You Need to Know About CA 19-9 and Cancer Diagnosis

5.

Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

2.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V

5.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot